Loading…
Academic Journal
Prospects of using C3435T polymorphism in the ABCB1 gene encoding P-glycoprotein in personalised medicine
R. E. Kazakov, V. A. Evteev, O. V. Muslimova, I. A. Mazerkina, E. Yu. Demchenkova, E. V. Shikh
Регуляторные исследования и экспертиза лекарственных средств, Vol 7, Iss 4, Pp 212-220 (2018)
Saved in:
| Title | Prospects of using C3435T polymorphism in the ABCB1 gene encoding P-glycoprotein in personalised medicine |
|---|---|
| Authors | R. E. Kazakov, V. A. Evteev, O. V. Muslimova, I. A. Mazerkina, E. Yu. Demchenkova, E. V. Shikh |
| Publication Year |
2018
|
| Source |
Регуляторные исследования и экспертиза лекарственных средств, Vol 7, Iss 4, Pp 212-220 (2018)
|
| Description |
The article reviews scientific literature on C3435T polymorphism in the ABCB1 gene which encodes P-glycoprotein (an ATP-binding cassette transporter which is responsible for energy-dependent transport of substrates across cellular membranes and whose primary role consists in the prevention of penetration of various substances, such as xenobiotics, through biological barriers. C3435T polymorphism in the ABCB1 gene could be regarded as a promising pharmacogenetic biomarker which could be used in diagnostic testing after approval of the corresponding test methods. The authors of the article collected and systematized scientific data available in the electronic media (NCBI PubMed, eLIBRARY.ru) regarding medicines (such as digoxin, fexofenadine, loperamide, amlodipine, statins, etc.) for which there are integrated pharmacogenetic data on the effect of C3435T polymorphism in the ABCB1 gene on pharmacokinetic parameters, as well as on the efficacy and safety of treatment. It was demonstrated that ABCB1 gene polymorphism is of great importance for personalised medicine, however, there is a lack of awareness about all the factors that affect the bioavailability of medicines, and this precludes a significant progress in the use of ABCB1 genotyping in the near future.
|
| Document Type |
article
|
| Language |
Russian
|
| Publisher Information |
Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’), 2018.
|
| Subject Terms | |
